Long-term safety of early consumption of Lactobacillus fermentum CECT5716: A 3-year follow-up of a randomized controlled trial

Maldonado-Lobón, Jose A.; Gil-Campos, Mercedes; Maldonado, J.; López‐Huertas, Eduardo; Flores-Rojas, Katherine; Valero, Antonio D.; Rodríguez-Benítez, M.V.; Bañuelos, Óscar; Lara-Villoslada, Federico; Fonolla, J.; Olivares, Mónica

doi:10.1016/j.phrs.2015.01.006

Cited by 43 publications

(33 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…L . fermentum is safe up to a level of 10 10 CFU/kg body weight/day during 2–4 weeks of treatment in animals, and it has also been shown to be safe in infant formulas in 1–6-month old infants [ 38 , 39 ]. It enables harmful intestinal bacterial enzymes to be inhibited, decreases pathogenic bacterial populations, and increases beneficial bacterial populations [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Synbiotic effects of β-glucans from cauliflower mushroom and Lactobacillus fermentum on metabolic changes and gut microbiome in estrogen-deficient rats

et al. 2017

View full text Add to dashboard Cite

BackgroundWe investigated whether the long-term consumption of a symbiotic formulation with Lactobacillus fermentum (probiotic) and β-glucan from cauliflower mushroom (prebiotic) would delay the progression of post-menopausal symptoms in ovariectomized (OVX) rats and explored their mechanisms of action, including changes in gut microbiota.MethodsOVX rats were fed with high-fat diets containing 1% dextrin (control), 1% lyophilized cauliflower mushroom extract (CFM), 0.1% L. fermentum JS (LFE), 1% CFM plus 0.1% LFE (CFLF), or 30 μg 17β-estradiol/kg body weight (positive-control) for 8 weeks.ResultsCFM contained 95.8% β-glucans. OVX increased the ratio of Firmicutes and Bacteroidetes in the large intestines. Only CFLF lowered tail skin temperature without increasing serum 17β-estradiol and uterine index. Visceral fat mass was lower in CFLF and positive-control groups by increasing daily energy expenditure and fat oxidation. Dyslipidemia induced by OVX was improved by CFM and CFLF as much as in the positive-control group. Homeostasis model assessment estimate of insulin resistance was lower in CFLF than in the positive-control. Hepatic insulin signaling (pAkt➔GSK-3β) was potentiated in the ascending order of the control, LFE, CFM, CFLF, and positive-control. AMPK phosphorylation showed similar patterns of hepatic insulin signaling but LFE increased it more than CFM. The changes in gut microbiota were prevented by CFLF in OVX rats, and the ratio of Firmicutes and Bacteroidetes in the CFLF was similar to the positive-control group.ConclusionOVX changed gut microbiota and was associated with menopausal symptoms; however, the synbiotics, CFM and LFE, prevented menopausal symptoms and improved the gut microbiota in estrogen-deficient rats.

show abstract

Section: Discussionmentioning

confidence: 99%

Synbiotic effects of β-glucans from cauliflower mushroom and Lactobacillus fermentum on metabolic changes and gut microbiome in estrogen-deficient rats

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A follow-up study that lasted 3 years observed similar values of growth, frequency of infectious and non-infectious diseases in children that received the L. fermentum CECT5716 formula compared with placebo [ 47 ]. The proposed mechanism of action was the innate response activation through the L. fermentum CECT5716 plus GOS, although no changes in fecal IgA were detected [ 47 ]. The effects of L. salivarius CECT5713 were mediated through butyric acid production, and a L. fermentum CECT5716 plus GOS treatment appeared to produce changes in the intestinal microbiota.…”

Section: Resultsmentioning

confidence: 99%

“…Additionally, we have studied the early administration of L. fermentum CECT5716, which is a probiotic strain added in infant formula, in children. We reported that this probiotic preparation was safe and it did not produce quantifiable differences in children compared with the control group, but no specific mechanism of action was addressed [ 47 , 89 ].…”

Section: Resultsmentioning

confidence: 99%

Immune-Mediated Mechanisms of Action of Probiotics and Synbiotics in Treating Pediatric Intestinal Diseases

et al. 2018

View full text Add to dashboard Cite

The pediatric population is continually at risk of developing infectious and inflammatory diseases. The treatment for infections, particularly gastrointestinal conditions, focuses on oral or intravenous rehydration, nutritional support and, in certain case, antibiotics. Over the past decade, the probiotics and synbiotics administration for the prevention and treatment of different acute and chronic infectious diseases has dramatically increased. Probiotic microorganisms are primarily used as treatments because they can stimulate changes in the intestinal microbial ecosystem and improve the immunological status of the host. The beneficial impact of probiotics is mediated by different mechanisms. These mechanisms include the probiotics’ capacity to increase the intestinal barrier function, to prevent bacterial transferation and to modulate inflammation through immune receptor cascade signaling, as well as their ability to regulate the expression of selected host intestinal genes. Nevertheless, with respect to pediatric intestinal diseases, information pertaining to these key mechanisms of action is scarce, particularly for immune-mediated mechanisms of action. In the present work, we review the biochemical and molecular mechanisms of action of probiotics and synbiotics that affect the immune system.

show abstract

“…Efficacy varies greatly between strains of bacteria used; however, the use has been shown to be safe even if there is no observable effect on health outcomes. [33][34][35][36] A study on infants less than 3 months old at enrollment who received Bifidobacterium infantis IM1 in a dose of 10 7 colony-forming units (cfu) per gram for 12 weeks had less incidence of diarrhea, reduction in Proteobacteria in stool samples, and higher stool frequency when compared to the control arm. 35 Additionally, synbiotics, the use of both probiotics and prebiotic, have shown additive beneficial effects.…”

Section: Probioticsmentioning

confidence: 99%

<p>Insights into Novel Infant Milk Formula Bioactives</p>

Skolnick¹,

Chou²,

Miklavcic³

2020

NDS

View full text Add to dashboard Cite

Human milk provides optimal infant nutrition for early life development. However, there are situations in which human milk feeding is not the most viable option for infant nutrition. Some factors include maternal illness, lactation insufficiency, storage complications, and time constraints. As a result, modern infant formula has become a substitute or alternative when breastfeeding is not possible or is inadequate for infants. In the optimal design of formula, many factors are considered in creating a product that is safe and provides a nutritional profile either equivalent to human milk or in optimal alignment with infant needs. Human milk composition serves as a reference for infant formula formulation. The purpose of this literature review is to provide a synopsis of recent advances in infant formula research in the past 5 years (2014)(2015)(2016)(2017)(2018). Specifically, the breadth of bioactive components of human milk that are not yet available in infant formulas and dose optimization requirements in full-term infants are reviewed. The nutritional value of infant formulas has been improved by adding functional bioactive ingredients such as choline, strains of probiotics, and prebiotic oligosaccharides. There are considerable variations in the composition of available infant formulas between manufacturers and across different countries. Formulas still generally lack important contents such as antibodies and exosomes that are present in human milk. Some of the adverse health outcomes associated with formula feeding as compared with human milk feeding are attributed to the different composition of the foods. This literature review summarizes the most recent research aimed at advancing infant formula composition to narrow the difference in health outcomes between human milk and formula-fed infants.

show abstract

Long-term safety of early consumption of Lactobacillus fermentum CECT5716: A 3-year follow-up of a randomized controlled trial

Cited by 43 publications

References 33 publications

Synbiotic effects of β-glucans from cauliflower mushroom and Lactobacillus fermentum on metabolic changes and gut microbiome in estrogen-deficient rats

Synbiotic effects of β-glucans from cauliflower mushroom and Lactobacillus fermentum on metabolic changes and gut microbiome in estrogen-deficient rats

Immune-Mediated Mechanisms of Action of Probiotics and Synbiotics in Treating Pediatric Intestinal Diseases

<p>Insights into Novel Infant Milk Formula Bioactives</p>

Contact Info

Product

Resources

About